INTI — Inhibitor Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $6.90m
- $3.17m
Annual income statement for Inhibitor Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.06 | 0.284 | -12.2 | 3.4 | 3.66 |
| Operating Profit | -1.06 | -0.284 | 12.2 | -3.4 | -3.66 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.06 | -0.299 | 12.2 | -3.03 | -3.34 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.06 | -0.299 | 12.1 | -3.03 | -3.34 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.06 | -0.299 | 12.1 | -3.03 | -3.34 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.26 | -0.499 | 11.9 | -3.03 | -3.34 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.003 | -0.001 | 0.01 | -0.018 | -0.019 |